Alnylam Pharmaceuticals Inc (ALNY)
269.93
-3.98
(-1.45%)
USD |
NASDAQ |
Nov 04, 16:00
273.63
+3.70
(+1.37%)
Pre-Market: 09:03
Alnylam Pharmaceuticals Free Cash Flow: 16.06M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | 16.06M |
| June 30, 2024 | 318.87M |
| March 31, 2024 | 127.82M |
| December 31, 2023 | 41.94M |
| September 30, 2023 | -66.56M |
| June 30, 2023 | -540.68M |
| March 31, 2023 | -604.65M |
| December 31, 2022 | -613.33M |
| September 30, 2022 | -631.75M |
| June 30, 2022 | -660.05M |
| March 31, 2022 | -654.28M |
| December 31, 2021 | -718.06M |
| September 30, 2021 | -690.85M |
| June 30, 2021 | -653.50M |
| March 31, 2021 | -672.38M |
| December 31, 2020 | -685.32M |
| September 30, 2020 | -775.30M |
| June 30, 2020 | -871.24M |
| March 31, 2020 | -451.80M |
| December 31, 2019 | -418.58M |
| September 30, 2019 | -371.77M |
| June 30, 2019 | -352.30M |
| March 31, 2019 | -745.14M |
| December 31, 2018 | -689.50M |
| September 30, 2018 | -625.30M |
| Date | Value |
|---|---|
| June 30, 2018 | -550.13M |
| March 31, 2018 | -527.43M |
| December 31, 2017 | -487.00M |
| September 30, 2017 | -461.44M |
| June 30, 2017 | -433.23M |
| March 31, 2017 | -413.30M |
| December 31, 2016 | -372.26M |
| September 30, 2016 | -330.20M |
| June 30, 2016 | -295.21M |
| March 31, 2016 | -269.16M |
| December 31, 2015 | -202.09M |
| September 30, 2015 | -186.09M |
| June 30, 2015 | -169.15M |
| March 31, 2015 | -160.90M |
| December 31, 2014 | -174.60M |
| September 30, 2014 | -157.69M |
| June 30, 2014 | -136.45M |
| March 31, 2014 | -111.96M |
| December 31, 2013 | -72.66M |
| September 30, 2013 | -119.01M |
| June 30, 2013 | -96.87M |
| March 31, 2013 | -96.25M |
| December 31, 2012 | -123.96M |
| September 30, 2012 | -80.04M |
| June 30, 2012 | -108.82M |
Free Cash Flow Range, Past 5 Years
-871.24M
Minimum
Jun 2020
318.87M
Maximum
Jun 2024
-460.18M
Average
-622.54M
Median
Free Cash Flow Benchmarks
| Pfizer Inc | 4.81B |
| Regeneron Pharmaceuticals Inc | 3.319B |
| BridgeBio Pharma Inc | -419.68M |
| Biomarin Pharmaceutical Inc | 300.88M |
| Johnson & Johnson | 19.02B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 43.71M |
| Cash from Investing (Quarterly) | -30.25M |
| Cash from Financing (Quarterly) | 102.76M |
| Free Cash Flow Per Share (Quarterly) | 0.3073 |
| Free Cash Flow to Equity (Quarterly) | 38.55M |
| Free Cash Flow to Firm (Quarterly) | 41.80M |
| Free Cash Flow Yield | 0.05% |